Recent advances in MeCP2 structure and function - PubMed (original) (raw)
Review
Recent advances in MeCP2 structure and function
Kristopher C Hite et al. Biochem Cell Biol. 2009 Feb.
Abstract
Mutations in methyl DNA binding protein 2 (MeCP2) cause the neurodevelopmental disorder Rett syndrome (RTT). The mechanism(s) by which the native MeCP2 protein operates in the cell are not well understood. Historically, MeCP2 has been characterized as a proximal gene silencer with 2 functional domains: a methyl DNA binding domain and a transcription repression domain. However, several lines of new data indicate that MeCP2 structure and function relationships are more complex. In this review, we first discuss recent studies that have advanced understanding of the basic structural biochemistry of MeCP2. This is followed by an analysis of cell-based experiments suggesting MeCP2 is a regulator, rather than a strict silencer, of transcription. The new data establish MeCP2 as a multifunctional nuclear protein, with potentially important roles in chromatin architecture, regulation of RNA splicing, and active transcription. We conclude by discussing clinical correlations between domain-specific mutations and RTT pathology to stress that all structural domains of MeCP2 are required to properly mediate cellular function of the intact protein.
Figures
Fig. 1
Chronological representation of known MeCP2 functions. The progression of traditional understanding of MeCP2 as a methyl-dependent proximal gene silencer is shown in grey on the left, while studies implicating MeCP2 as having additional functions are listed on the right. CTD, carboxyl terminal domain.
Fig. 2
Diagram of MeCP2 domain organization, based on biochemical data aligned with a FoldIndex plot. Domains are labeled from amino to carboxyl terminal from left to right. The location and sequence of the alternatively spliced region of the e1 and e2 isoforms is shown at the left. The boundaries of trypsin-resistant bands are indicated by black diamonds. The full-length protein sequence was analyzed by the FoldIndex algorithm (
http://bioportal.weizmann.ac.il/fldbin/findex
), with a window setting of 10 and a step value of 1. Regions that are predicted to be disordered are indicated in black, while ordered regions are shown in gray. Note that under these settings, the first and last 10 amino acids are not represented in the plot.
Fig. 3
Schematic depicting MeCP2 with contingent domains labeled. Two common Rett syndrome (RTT) truncation mutations (R168X and R294X) and an RTT point mutation (R306C) are indicated along the peptide. The phenotypic pathology or combinations are correlated to each mutation with symbols.
Similar articles
- Biophysical characterization of the basic cluster in the transcription repression domain of human MeCP2 with AT-rich DNA.
Mushtaq AU, Lee Y, Hwang E, Bang JK, Hong E, Byun Y, Song JJ, Jeon YH. Mushtaq AU, et al. Biochem Biophys Res Commun. 2018 Jan 1;495(1):145-150. doi: 10.1016/j.bbrc.2017.10.169. Epub 2017 Oct 31. Biochem Biophys Res Commun. 2018. PMID: 29101034 - Analysis of protein domains and Rett syndrome mutations indicate that multiple regions influence chromatin-binding dynamics of the chromatin-associated protein MECP2 in vivo.
Kumar A, Kamboj S, Malone BM, Kudo S, Twiss JL, Czymmek KJ, LaSalle JM, Schanen NC. Kumar A, et al. J Cell Sci. 2008 Apr 1;121(Pt 7):1128-37. doi: 10.1242/jcs.016865. Epub 2008 Mar 11. J Cell Sci. 2008. PMID: 18334558 Free PMC article. - Molecular Context-Dependent Effects Induced by Rett Syndrome-Associated Mutations in MeCP2.
Ortega-Alarcon D, Claveria-Gimeno R, Vega S, Jorge-Torres OC, Esteller M, Abian O, Velazquez-Campoy A. Ortega-Alarcon D, et al. Biomolecules. 2020 Nov 10;10(11):1533. doi: 10.3390/biom10111533. Biomolecules. 2020. PMID: 33182787 Free PMC article. - Modeling Rett Syndrome Using Human Induced Pluripotent Stem Cells.
Andoh-Noda T, Inouye MO, Miyake K, Kubota T, Okano H, Akamatsu W. Andoh-Noda T, et al. CNS Neurol Disord Drug Targets. 2016;15(5):544-50. doi: 10.2174/1871527315666160413120156. CNS Neurol Disord Drug Targets. 2016. PMID: 27071793 Review. - Binding of the Rett syndrome protein, MeCP2, to methylated and unmethylated DNA and chromatin.
Hansen JC, Ghosh RP, Woodcock CL. Hansen JC, et al. IUBMB Life. 2010 Oct;62(10):732-8. doi: 10.1002/iub.386. IUBMB Life. 2010. PMID: 21031501 Free PMC article. Review.
Cited by
- Extending MeCP2 interactome: canonical nucleosomal histones interact with MeCP2.
Ortega-Alarcon D, Claveria-Gimeno R, Vega S, Kalani L, Jorge-Torres OC, Esteller M, Ausio J, Abian O, Velazquez-Campoy A. Ortega-Alarcon D, et al. Nucleic Acids Res. 2024 Apr 24;52(7):3636-3653. doi: 10.1093/nar/gkae051. Nucleic Acids Res. 2024. PMID: 38321951 Free PMC article. - Comprehensive analysis reveals the prognostic and immunogenic characteristics of DNA methylation regulators in lung adenocarcinoma.
Huang J, Huang C, Huang C, Xiang Z, Ni Y, Zeng J, Cai S. Huang J, et al. Respir Res. 2024 Feb 5;25(1):74. doi: 10.1186/s12931-024-02695-4. Respir Res. 2024. PMID: 38317133 Free PMC article. - KW-2449 and VPA exert therapeutic effects on human neurons and cerebral organoids derived from MECP2-null hESCs.
Xu YJ, Liu PP, Yan ZZ, Mi TW, Wang YY, Li Q, Teng ZQ, Liu CM. Xu YJ, et al. Stem Cell Res Ther. 2022 Dec 27;13(1):534. doi: 10.1186/s13287-022-03216-0. Stem Cell Res Ther. 2022. PMID: 36575558 Free PMC article. - MECP2 promotes the migration and invasion of gastric cancer cells by modulating the Notch1/c-Myc/mTOR signaling pathways by suppressing FBXW7 transcription.
Zhao L, Wang X, Yang J, Jiang Q, Zhang J, Wu F, Ni L, Tong D, Huang C. Zhao L, et al. Am J Cancer Res. 2022 Nov 15;12(11):5183-5204. eCollection 2022. Am J Cancer Res. 2022. PMID: 36504898 Free PMC article. - R306X Mutation in the MECP2 Gene Causes an Atypical Rett Syndrome in a Moroccan Patient: A Case Report.
Bouzroud W, Tazzite A, Berrada S, Gazzaz B, Dehbi H. Bouzroud W, et al. Clin Pathol. 2022 Sep 16;15:2632010X221124269. doi: 10.1177/2632010X221124269. eCollection 2022 Jan-Dec. Clin Pathol. 2022. PMID: 36147795 Free PMC article.
References
- Abuhatzira L, Makedonski K, Kaufman Y, Razin A, Shemer R. MeCP2 deficiency in the brain decreases BDNF levels by REST/CoREST-mediated repression and increases TRKB production. Epigenetics. 2007;2:214–222. - PubMed
- Archer H, Evans J, Leonard H, Colvin L, Ravine D, Christodoulou J, et al. Correlation between clinical severity in patients with Rett syndrome with a p.R168X or p.T158M MECP2 mutation, and the direction and degree of skewing of X-chromosome inactivation. J Med Genet. 2007;44:148–152. doi: 10.1136/jmg.2006.045260. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources